Ligand-based therapies work by specifically targeting cancer cells, thereby minimizing damage to normal cells. This specificity is achieved through the ligand's ability to bind only to cancer-specific receptors or proteins. These therapies can block signal transduction pathways, induce apoptosis, or deliver cytotoxic agents directly to cancer cells.
